Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Licenses Polypeptide Nanoparticle Delivery Technology from University of Maryland Medical School

Premium

Sirnaomics said this week that it has licensed a polypeptide nanoparticle delivery technology developed at the University of Maryland Medical School.

"The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of histidine-lysine polymer for siRNA therapeutics in the areas of wound healing and ocular diseases," the company said.

"Licensing the histidine-lysine polymer nanoparticle technology is rooted in our long-time experience and in-depth understanding of this unique class of polypeptides as an siRNA delivery vehicle," Sirnaomics President and CEO Patrick Lu said in a statement. "We are currently engaging in several similar collaborative efforts and we believe that this is a great way to create value and ensure the credibility of a novel technology."

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.